Biodistribution and antitumour efficacy of long-circulating N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in nude mice

European Journal of Cancer

Volumn 37, Issue 1, 2001, Pages 131-139

  Shiah, J G ^a   Dvorak M ^a   Kopeckova P ^a   Sun, Y ^c   Peterson, C M ^b   Kopecek J ^a  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Doxorubicin; EPR effect; Long circulating conjugate; N (2 hydroxypropyl)methacrylamide copolymer; Ovarian carcinoma

Indexed keywords

CROSS LINKING REAGENT; DOXORUBICIN; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; N2,N5 BIS(N METHACRYLOYLGLYCYLPHENYLALANYLLEUCYLGLYCYL)ORNITHINE METHYL ESTER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TISSUE LEVEL; FEMALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; OVARY CARCINOMA; POLYMERIZATION; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; DOXORUBICIN; FEMALE; MICE; MICE, NUDE; OVARIAN NEOPLASMS; POLYMETHACRYLIC ACIDS;

EID: 0035145742     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00374-9     Document Type: Article

References (32)

1. HPMA copolymer-anticancer drug conjugates: Design, activity, and mechanism of action
2. Polymer conjugates with anticancer activity
3. Phase I clinical and pharmacokinetic study of PK1 (HPMA copolymer-doxorubicin): First member of a new class of chemotherapeutic agents - Drug-polymer conjugates
4. Early phase tumor accumulation of macromolecules: A great difference in clearance rate between tumor and normal tissues
5. 6 and adriamycin in nude mice bearing human ovarian carcinoma OVCAR-3 xenografts
6. A long-circulating co-polymer in 'passive targeting' to solid tumors
7. Conjugates of anticancer agents and polymers: Advantages of macromolecular therapeutics in vivo
8. New types of synthetic infusion solutions. III. Elimination and retention of poly[N-(2-hydroxypropyl)methacrylamide] in a test organism
9. High-molecular weight HPMA copolymer-adriamycin conjugates
10. Combination chemotherapy and photodynamic therapy with N-(2-hydroxypropyl)methacrylamide copolymer-bound anticancer drugs inhibit human ovarian carcinoma heterotransplanted in nude mice
11. 6 and adriamycin conjugates in combination therapy
12. Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma
13. Electric charge influence of dextran derivatives on their tumor accumulation after intravenous injection
14. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
15. The influence of cytotoxicity of macromolecules and of VEGF gene modulated vascular permeability on the enhanced permeability and retention effect in resistant solid tumor
16. A polymeric drug delivery system for the simultaneous delivery of drugs activatable by enzymes and/or light
17. Soluble, crosslinked N-(2-hydroxypropyl)methacrylamide copolymers as potential drug carriers. 1. Pinocytosis by rat visceral yolk sacs and rat intestine cultured in vitro. Effect of molecular weight on uptake and intracellular degradation
18. Soluble, crosslinked N-(2-hydroxypropyl)methacrylamide copolymers as potential drug carriers. 2. Effect of molecular weight on blood clearance and body distribution in the rat after intravenous administration. Distribution of unfractionated copolymer after intraperitoneal, subcutaneous or oral administration
19. Soluble, crosslinked N-(2-hydroxypropyl)methacrylamide copolymers as potential drug carriers. 3. Targeting by incorporation of galactosamine residues. Effect of route of administration 2
20. W) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats
21. Polymers containing enzymatically degradable bonds. 4. Preliminary experiments in vivo
22. Polymers containing enzymatically degradable bonds. 8. Degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B
23. Cleavage of oligopeptide side-chains in N-(2-hydroxypropyl)methacrylamide copolymers by mixtures of lysosomal enzymes
24. Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: An experimental study in the rat
25. Delivery of molecular and cellular medicine to solid tumors
26. Role of tumor vascular architecture in nutrient and drug delivery: An invasion percolation-based network model
27. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions
28. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 2. Processing in epithelial ovarian carcinoma cells in vitro
29. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats
30. 2 conjugates and combined therapy with immunomodulators
31. Polymerizable Fab' antibody fragments for targeting of anticancer drugs